<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0085">
 <label>17</label>
 <mixed-citation publication-type="other" id="or0010">Cerus Corporation; Emory University. A prospective, open label, phase 1 safety study of passive immune therapy during acute Ebola virus infection using transfusion of INTERCEPT plasma prepared from volunteer donors who have recovered from Ebola virus disease. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US). NLM Identifier: NCT02295501; 2000 [cited 2019 February 6]. 
  <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02295501?term1/4ebolaþplasma&amp;rank1/42" id="ir0005" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT02295501?term1/4ebolaþplasma&amp;rank1/42</ext-link>.
 </mixed-citation>
</ref>
